Relay Therapeutics, Inc.
NASDAQ:RLAYBiotechnology
+$0.41 today
- Market cap
- $3.65B
- Beta
- 1.75
- P/E (TTM)
- -10.5
- EPS (TTM)
- -$1.52
Volume 2.43M
Average 3.70M
RLAY EBITDA Margin
EBITDA as a percentage of revenue.
Relay Therapeutics, Inc.NASDAQ: RLAY
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin narrows to -23813.4%
EBITDA Margin was -23813.4% in Q2 FY2026, down 13566.3 pp from a year earlier. On a trailing-twelve-month basis it was -2742.3%, up 927.4 pp year over year. Over 3 fiscal years it widened by 20440.0 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 8 analysts of -2684.3% for the fiscal year ending Dec 2026, down from -1777.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -23813.4%-21387.2 pp QoQ
- Last fiscal yearDec 2025
- -1777.4%+2022.0 pp YoY
- LTMJun 2026
- -2742.3%+927.4 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -1777.4%
- Year-over-year change
- +2022.0pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -1777.4% | +2022.0pp |
| FY2024 | 2024-12-31 | -3799.4% | -2334.8pp |
| FY2023 | 2023-12-31 | -1464.6% | +20752.8pp |
| FY2022 | 2022-12-31 | -22217.4% | -14852.5pp |
| FY2021 | 2021-12-31 | -7364.9% | — |
EBITDA Margin vs competitors
How RLAY compares with its peers on the latest reported figures
- RLAY's LTM Jun 2026 EBITDA Margin of -2742.3% is the lowest of the 6 companies compared; the peer median is -159.2%.
- Its year-over-year change of +927.4 pp is the 3rd highest of 6, against a peer median of +319.7 pp.
- Over three fiscal years its change of +20440.0 pp compares with a peer median of +104.3 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Aug 2026 | 46.0% | +315.4 pp | +147.4 pp | |
| LTM Mar 2026 | -60.1% | +4260.2 pp | +61.2 pp | |
| FY2025 | -159.2% | +144.1 pp | +269.3 pp | |
| LTM Jun 2026 | -277.6% | +319.7 pp | -449.2 pp | |
| LTM Mar 2026 | -455.3% | +1345.3 pp | — | |
| LTM Jun 2026 | -2742.3% | +927.4 pp | +20440.0 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding RLAY) | -159.2% | +319.7 pp | +104.3 pp | |
Competitors are the stored peer set for RLAY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.03M | 1.38M | 25.55M | 10.01M | 15.36M |
| Cost of Revenue | 169.39M | 243.01M | 326.39M | 315.44M | 3.56M |
| Gross Profit | (166.36M) | (241.62M) | (300.84M) | (305.43M) | 11.8M |
| Gross Margin | -5492.2% | -17496.3% | -1177.6% | -3052.2% | 76.8% |
| Research & Development | 295.65M | 246.36M | 330.02M | 319.09M | 261.38M |
| Selling, General & Admin | 59.75M | 69.33M | 78.58M | 80.24M | 56.71M |
| Operating Expenses | 198.34M | 57.65M | 72.16M | 67.03M | 314.54M |
| Depreciation & Amortization | 3.93M | 4.13M | 5.27M | 5.46M | 3.56M |
| EBITDA | (223.08M) | (306.82M) | (374.15M) | (380.21M) | (272.92M) |
| EBITDA Margin | -7364.9% | -22217.4% | -1464.6% | -3799.4% | -1777.4% |
| Operating Income | (364.7M) | (299.28M) | (373M) | (372.47M) | (302.74M) |
| Operating Margin | -12040.2% | -21670.9% | -1460.1% | -3722.1% | -1971.6% |
| Interest Income | 830K | 8.79M | 31.05M | 34.75M | 27.04M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 826K | 8.77M | 31.03M | 34.76M | 26.26M |
| Income Before Tax | (363.87M) | (290.51M) | (341.97M) | (337.71M) | (276.48M) |
| Pre-Tax Margin | -12012.9% | -21036.1% | -1338.7% | -3374.7% | -1800.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (363.87M) | (290.51M) | (341.97M) | (337.71M) | (276.48M) |
| Net Margin | -12012.9% | -21036.1% | -1338.7% | -3374.7% | -1800.6% |
| EPS (Basic) | (3.82) | (2.59) | (2.79) | (2.36) | (1.61) |
| EPS (Diluted) | (3.82) | (2.59) | (2.79) | (2.36) | (1.61) |
| Weighted Avg Shares | 95.14M | 112.23M | 122.58M | 142.87M | 171.59M |
| Weighted Avg Shares (Diluted) | 95.14M | 112.23M | 122.58M | 142.87M | 171.59M |
Relay Therapeutics, Inc.
NASDAQ:RLAY
Intrinsic Alpha fair value
Locked
Current Price
$16.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.